Outcomes of patients with borderline-resectable pancreatic cancer treated with FOLFIRINOX versus gemcitabine plus nab-paclitaxel.
Shaina D'Lee Templeton(University of Saskatchewan), Shahid Ahmed(Emory University), Mike Moser(Roswell Park Comprehensive Cancer Center), John M. Shaw(University of Saskatchewan), Adnan Zaidi(University of Saskatchewan), Yigang Luo(University of Saskatchewan), Haji Chalchal
Cited by 1
Related Papers
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Obesity and Cancer: A Current Overview of Epidemiology, Pathogenesis, Outcomes, and Management
|Cancers|2023|640
Gallbladder Cancer in the 21st Century
|Journal of Oncology|2015|301
A Randomized Clinical Trial of Granulocyte Transfusions for Infection in Acute Leukemia
|New England Journal of Medicine|1977|299
The Genotype-Tissue Expression (GTEx) project
|Nature Genetics|2013|266